2023-07-18 09:46:37
The listing of the action of the biotech argenx, specializing in the treatment of autoimmune diseases and cancer, was suspended on Tuesday on the Brussels Stock Exchange, announced the FSMA, the stock market policeman.
The suspension took effect at 9 a.m. Tuesday and came pending the publication of a press release.
The announcement of encouraging results around a new drug made the argenx share jump by more than 31% on Monday on the Brussels Stock Exchange.
After the success of a clinical trial which boosted its action on Monday (+31%), argenx launched a global offer on Monday evening to raise 750 million dollars.
1689680644
#company #raise #million #dollars #action #suspended #Brussels #Stock #Exchange
Related posts:
Polynesia: The State appoints Vinci as concessionaire of Tahiti-Faa'a airport, an appeal will be fil...
Inflation rebounds in April -
The Lufthansa Group Achieves Record Results and Expects Strong Annual Performance
Honda HR-V and WR-V ended their current production in Brazil
15% increase in animal abandonment in March
Why bother using your smartphone... The world will completely change in 5 years
Microsoft's Financial Support for OpenAI: EU Merger Rules and Competition Concerns
Creating an Air Outre-mer Supercompany for Overseas Territories: The Pros and Cons